BUDGET IMPACT ANALYSIS OF TRIVERAM FOR THE TREATMENT OF HYPERTENSION IN ITALY

被引：0
|
作者：
Lanati, E. P. [1 ]
Orlando, V. L. [1 ]
Doratori, S. [2 ]
机构：
[1] MA Provider Srl, Milan, Italy
[2] Servier Italia, Rome, Italy
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV41
引用
收藏
页码：A643 / A643
页数：1
相关论文
共 50 条
  • [21] A BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF GENERIC BOSENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Tsakalogiannis, C.
    Ollandezos, M.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2016, 19 (07) : A580 - A580
  • [22] Budget Impact Model of riociguat (Adempas®) in Pulmonary Arterial Hypertension (PAH) in Italy
    Poscia, R.
    Vizza, C. D.
    Di Matteo, S.
    Oselin, M.
    Bruno, G. M.
    D'Alto, M.
    Ghio, S.
    Colombo, G. L.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2018, 28 : 461 - 461
  • [23] Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
    Fiorentino, Francesca
    Di Rienzo, Paolo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 29 - 39
  • [24] BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
    Bellone, M.
    Pradelli, L.
    Recchia, A.
    Caputo, A.
    Masetti, L.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [25] BUDGET IMPACT ANALYSIS OF THE USE OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA IN ITALY
    D'Ambrosio, F.
    Bini, C.
    Marcellusi, A.
    Mennini, F. S.
    VALUE IN HEALTH, 2018, 21 : S248 - S248
  • [26] A BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF GENERICS AMBRISENTAN AND TADALAFIL FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN GREECE
    Nomikos, N.
    Kyriopoulos, I
    Athanasakis, K.
    VALUE IN HEALTH, 2022, 25 (12) : S103 - S103
  • [27] RENAL DENERVATION WITH THE SYMPLICITY CATHETER SYSTEM FOR TREATMENT-RESISTANT HYPERTENSION: A BUDGET IMPACT ANALYSIS
    Naclerio, M.
    Corbo, M.
    Beccagutti, G.
    VALUE IN HEALTH, 2014, 17 (07) : A480 - A480
  • [28] BUDGET IMPACT MODEL OF OMALIZUMAB IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN ITALY
    Ravasio, R.
    Cawson, M. R.
    McBride, D.
    Balp, M.
    Roccia, A.
    VALUE IN HEALTH, 2015, 18 (07) : A417 - A417
  • [29] Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
    Cortesi, Paolo Angelo
    Antonazzo, Ippazio Cosimo
    Gasperini, Claudio
    Nica, Mihaela
    Ritrovato, Daniela
    Mantovani, Lorenzo Giovanni
    PLOS ONE, 2022, 17 (03):
  • [30] Budget impact analysis of the adoption of new hypertension guidelines in Colombia
    Augusto Guevara-Cuellar, Cesar
    Soto, Victoria Eugenia
    Isabel Molina-Echeverry, Maria
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
12345